| MultiLoc: prediction of protein subcellular localization using N-terminal targeting sequences, sequence motifs and amino acid composition A Höglund, P Dönnes, T Blum, HW Adolph, O Kohlbacher Bioinformatics 22 (10), 1158-1165, 2006 | 434 | 2006 |
| The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab B Ungar, Y Chowers, M Yavzori, O Picard, E Fudim, O Har-Noy, ... Gut 63 (8), 1258-1264, 2014 | 360 | 2014 |
| Prediction of MHC class I binding peptides, using SVMHC P Dönnes, A Elofsson BMC bioinformatics 3, 1-8, 2002 | 359 | 2002 |
| WIPI proteins: essential PtdIns3P effectors at the nascent autophagosome T Proikas-Cezanne, Z Takacs, P Dönnes, O Kohlbacher Journal of cell science 128 (2), 207-217, 2015 | 346 | 2015 |
| Predicting protein subcellular localization: past, present, and future P Dönnes, A Höglund Genomics, proteomics & bioinformatics 2 (4), 209-215, 2004 | 163 | 2004 |
| SherLoc: high-accuracy prediction of protein subcellular localization by integrating text and protein sequence data H Shatkay, A Höglund, S Brady, T Blum, P Dönnes, O Kohlbacher Bioinformatics 23 (11), 1410-1417, 2007 | 152 | 2007 |
| Machine learning techniques for personalised medicine approaches in immune-mediated chronic inflammatory diseases: applications and challenges J Peng, EC Jury, P Dönnes, C Ciurtin Frontiers in pharmacology 12, 720694, 2021 | 150 | 2021 |
| Barrier properties and transcriptome expression in human iPSC-derived models of the blood–brain barrier L Delsing, P Dönnes, J Sánchez, M Clausen, D Voulgaris, A Falk, ... Stem cells 36 (12), 1816-1827, 2018 | 113 | 2018 |
| SVMHC: a server for prediction of MHC-binding peptides P Dönnes, O Kohlbacher Nucleic acids research 34 (suppl_2), W194-W197, 2006 | 109 | 2006 |
| Integrated modeling of the major events in the MHC class I antigen processing pathway P Dönnes, O Kohlbacher Protein Science 14 (8), 2132-2140, 2005 | 102 | 2005 |
| Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease DE Matei, M Menon, DG Alber, AM Smith, B Nedjat-Shokouhi, A Fasano, ... Med 2 (7), 864-883. e9, 2021 | 92 | 2021 |
| Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines … Clinical & Experimental Immunology 181 (3), 385-400, 2015 | 84 | 2015 |
| Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach GA Robinson, J Peng, P Dönnes, L Coelewij, M Naja, A Radziszewska, ... The Lancet Rheumatology 2 (8), e485-e496, 2020 | 70 | 2020 |
| Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: a European retrospective multicohort analysis J Quistrebert, S Hässler, D Bachelet, C Mbogning, A Musters, PP Tak, ... Seminars in Arthritis and Rheumatism 48 (6), 967-975, 2019 | 70 | 2019 |
| Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19 S Havervall, H Ng, A Jernbom Falk, N Greilert‐Norin, A Månberg, ... Journal of internal medicine 291 (1), 72-80, 2022 | 65 | 2022 |
| A mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines NC Toussaint, P Dönnes, O Kohlbacher PLoS computational biology 4 (12), e1000246, 2008 | 58 | 2008 |
| Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium S Hässler, D Bachelet, J Duhaze, N Szely, A Gleizes, S Hacein-Bey Abina, ... PLoS Medicine 17 (10), e1003348, 2020 | 54 | 2020 |
| Plasma profiling reveals human fibulin-1 as candidate marker for renal impairment M Neiman, JJ Hedberg, PR Donnes, I Schuppe-Koistinen, S Hanschke, ... Journal of proteome research 10 (11), 4925-4934, 2011 | 53 | 2011 |
| Immunoinformatics: predicting immunogenicity in silico DR Flower Springer Science & Business Media, 2007 | 48 | 2007 |
| Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter Y Repessé, I Peyron, JD Dimitrov, S Dasgupta, EF Moshai, C Costa, ... haematologica 98 (10), 1650, 2013 | 45 | 2013 |
Oliver KohlbacherProfessor for Applied Bioinformatics, University of TübingenE-mail megerősítve itt: uni-tuebingen.de